Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin | BioMed Central Health and Quality of Life Outcomes Research Open Access Improvement in quality of life measures in patients with refractory hepatitis C responding to re-treatment with Pegylated interferon alpha -2b and ribavirin Abraham Mathew Laurie P Peiffer Kathy Rhoades and Thomas J McGarrity Address Division of Gastroenterology and Hepatology Department of Medicine Milton S. Hershey Medical Center Pennsylvania State University . Box 850 H045 Hershey 17033-0850 Pennsylvania USA Email Abraham Mathew - amathew@ Laurie P Peiffer - lpeiffer@ Kathy Rhoades - krhoades@ Thomas J McGarrity - tmcgarrity@ Corresponding author Published 12 May 2006 Received 07 November 2005 Health and Quality of Life Outcomes 2006 4 30 doi 1477-7525-4-30 Accepted 12 May 2006 This article is available from http content 4 1 30 2006 Mathew et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background In this paper we report the health related quality of life HRQOL data from patients with hepatitis C viral infection HCV who were refractory to prior therapy and had re-treatment with a combination of Pegylated interferon alpha-2b and ribavirin. We hypothesized that the HRQOL will improve in those patients who attain sustained viral response similar to naive patients undergoing treatment for HCV. Methods HRQOL data was obtained from 152 patients enrolled into a randomized study for re-treatment of HCV refractory to prior therapy with interferon alpha-2b in combination with ribavirin. The treatment protocol was for 48 weeks and had a high and low dose arm. The HRQOL data was collected at baseline weeks 24 and 48 of treatment and at 24 week follow-up after treatment. A repeated measures .
